A Novel Inflammatory-Nutritional Prognostic Scoring System for Patients with Early-Stage Breast Cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.21590
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Nozawa K, Yoshimura A, Iwata H. Adjuvant olaparib in BRCA-mutated breast cancer. N Engl J Med. 2021;385(15):1439. doi:10.1056/NEJMc2112373
   PubMed Web of Science ®Google Scholar
• Schmid P, Cortes J, Dent R, et al. VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab+ chemotherapy vs. placebo+ chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC. Ann Oncol. 2021;32(9):1198–1200.
   Web of Science ®Google Scholar
• Tolaney SM, Guo H, Pernas S, et al. Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor Receptor 2–positive breast cancer. J Clin Oncol. 2019;37(22):1868–1875. doi:10.1200/JCO.19.00066
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617–628. doi:10.1056/NEJMoa1814017
   PubMed Web of Science ®Google Scholar
• Sachs N, de Ligt J, Kopper O, et al. A living biobank of breast cancer organoids captures disease heterogeneity. Cell. 2018;172(1–2):373–86.e10. doi:10.1016/j.cell.2017.11.010
   PubMed Web of Science ®Google Scholar
• Cardoso F, Van’t Veer LJ, Bogaerts J, et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016;375(8):717–729. doi:10.1056/NEJMoa1602253
   PubMed Web of Science ®Google Scholar
• Sparano JA, Gray RJ, Makower DF, et al. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med. 2015;373(21):2005–2014. doi:10.1056/NEJMoa1510764
   PubMed Web of Science ®Google Scholar
• Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160–1167. doi:10.1200/JCO.2008.18.1370
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Pietrocola F, Kroemer G. Nutrition, inflammation and cancer. Nat Immunol. 2017;18(8):843–850. doi:10.1038/ni.3754
   PubMed Web of Science ®Google Scholar
• Wang N, Xi W, Lu S, et al. A Novel inflammatory-nutritional prognostic scoring system for Stage III gastric cancer patients with radical gastrectomy followed by adjuvant chemotherapy. Front Oncol. 2021;11:650562. doi:10.3389/fonc.2021.650562
   PubMed Web of Science ®Google Scholar
• Zhang N, Jiang J, Tang S, Sun G. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Int Immunopharmacol. 2020;85:106677. doi:10.1016/j.intimp.2020.106677
   PubMed Web of Science ®Google Scholar
• Rebuzzi SE, Signori A, Banna GL, et al. Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). Ther Adv Med Oncol. 2021;13:17588359211019642. doi:10.1177/17588359211019642
   Web of Science ®Google Scholar
• Templeton AJ, McNamara MG, Šeruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124. doi:10.1093/jnci/dju124
   PubMedGoogle Scholar
• Huang ZZ, Song CG, Huang JJ, et al. Prognostic significance of the Controlling Nutritional Status (CONUT) score in surgically treated breast cancer patients. Gland Surg. 2020;9(5):1370–1379. doi:10.21037/gs-20-294
   PubMed Web of Science ®Google Scholar
• Hua X, Long ZQ, Zhang YL, et al. Prognostic value of preoperative systemic immune-inflammation index in breast cancer: a propensity score-matching study. Front Oncol. 2020;10:580. doi:10.3389/fonc.2020.00580
   PubMed Web of Science ®Google Scholar
• van der Willik KD, Koppelmans V, Hauptmann M, Compter A, Ikram MA, Schagen SB. Inflammation markers and cognitive performance in breast cancer survivors 20 years after completion of chemotherapy: a cohort study. Breast Cancer Res. 2018;20(1):135. doi:10.1186/s13058-018-1062-3
   PubMed Web of Science ®Google Scholar
• Ethier JL, Desautels D, Templeton A, Shah PS, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Res. 2017;19(1):2. doi:10.1186/s13058-016-0794-1
   PubMed Web of Science ®Google Scholar
• Ma Y, Zhang J, Chen X. Lymphocyte-to-monocyte ratio is associated with the poor prognosis of breast cancer patients receiving neoadjuvant chemotherapy. Cancer Manag Res. 2021;13:1571–1580. doi:10.2147/CMAR.S292048
   PubMed Web of Science ®Google Scholar
• Huang ZZ, Hua X, Song CG, et al. The prognostic prediction value of systemic inflammation score and the development of a nomogram for patients with surgically treated breast cancer. Front Oncol. 2020;10:563731. doi:10.3389/fonc.2020.563731
   PubMed Web of Science ®Google Scholar
• Qi Q, Zhuang L, Shen Y, et al. A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. Cancer. 2016;122(14):2158–2167. doi:10.1002/cncr.30057
   PubMed Web of Science ®Google Scholar
• Hua X, Long ZQ, Huang X, et al. The preoperative systemic inflammation response index (SIRI) independently predicts survival in postmenopausal women with breast cancer. Curr Probl Cancer. 2020;44(4):100560. doi:10.1016/j.currproblcancer.2020.100560
   PubMed Web of Science ®Google Scholar
• Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J. 2010;9:69. doi:10.1186/1475-2891-9-69
   PubMed Web of Science ®Google Scholar
• Li D, Lv H, Hao X, Hu B, Song Y. Prognostic value of serum alkaline phosphatase in the survival of prostate cancer: evidence from a meta-analysis. Cancer Manag Res. 2018;10:3125–3139. doi:10.2147/CMAR.S174237
   PubMed Web of Science ®Google Scholar
• Long ZQ, Hua X, Zhang WW, et al. Prognostic impact of the pretreatment albumin to alkaline phosphatase ratio for nonmetastatic breast cancer patients. Cancer Manag Res. 2019;11:4809–4814. doi:10.2147/CMAR.S200759
   PubMed Web of Science ®Google Scholar
• Moore SC, Playdon MC, Sampson JN, et al. A metabolomics analysis of body mass index and postmenopausal breast cancer risk. J Natl Cancer Inst. 2018;110(6):588–597. doi:10.1093/jnci/djx244
   PubMedGoogle Scholar
• Chen L, Bai P, Kong X, et al. Prognostic Nutritional Index (PNI) in patients with breast cancer treated with neoadjuvant chemotherapy as a useful prognostic indicator. Front Cell Develop Biol. 2021;9:656741. doi:10.3389/fcell.2021.656741
   PubMed Web of Science ®Google Scholar
• Dowsett M, Nielsen TO, A’Hern R, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in breast cancer working group. J Natl Cancer Inst. 2011;103(22):1656–1664. doi:10.1093/jnci/djr393
   PubMed Web of Science ®Google Scholar
• Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol. 2020;38(12):1346–1366. doi:10.1200/JCO.19.02309
   PubMed Web of Science ®Google Scholar
• Woo JW, Lee K, Chung YR, Jang MH, Ahn S, Park SY. The updated 2018 American Society of Clinical Oncology/College of American Pathologists guideline on human epidermal growth factor receptor 2 interpretation in breast cancer: comparison with previous guidelines and clinical significance of the proposed in situ hybridization groups. Hum Pathol. 2020;98:10–21. doi:10.1016/j.humpath.2020.01.003
   PubMed Web of Science ®Google Scholar
• Hirahara N, Tajima Y, Fujii Y, et al. Controlling Nutritional Status (CONUT) as a prognostic immunonutritional biomarker for gastric cancer after curative gastrectomy: a propensity score-matched analysis. Surg Endosc. 2019;33(12):4143–4152. doi:10.1007/s00464-019-06723-z
   PubMed Web of Science ®Google Scholar
• Hothorn T, Zeileis A. Generalized maximally selected statistics. Biometrics. 2008;64(4):1263–1269. doi:10.1111/j.1541-0420.2008.00995.x
   PubMed Web of Science ®Google Scholar
• Wileyto EP, Li Y, Chen J, Heitjan DF. Assessing the fit of parametric cure models. Biostatistics (Oxford, England). 2013;14(2):340–350. doi:10.1093/biostatistics/kxs043
   PubMed Web of Science ®Google Scholar
• Velazquez-Caldelas TE, Alcalá-Corona SA, Espinal-Enríquez J, Hernandez-Lemus E. Unveiling the link between inflammation and adaptive immunity in breast cancer. Front Immunol. 2019;10:56. doi:10.3389/fimmu.2019.00056
   PubMed Web of Science ®Google Scholar
• Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493–503. doi:10.1016/S1470-2045(14)70263-3
   PubMed Web of Science ®Google Scholar
• Li WZ, Hua X, Lv SH, et al. A scoring system based on nutritional and inflammatory parameters to predict the efficacy of first-line chemotherapy and survival outcomes for De Novo metastatic Nasopharyngeal carcinoma. J Inflamm Res. 2021;14:817–828. doi:10.2147/JIR.S296710
   PubMed Web of Science ®Google Scholar
• Kim JH, Son NH, Lee JS, et al. Time-sequencing of the neutrophil-to-lymphocyte ratio to predict prognosis of triple-negative breast cancer. Cancers (Basel). 2021;13:14. doi:10.3390/cancers13143472
   Web of Science ®Google Scholar
• Ligorio F, Fucà G, Zattarin E, et al. The pan-immune-inflammation-value predicts the survival of patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive advanced breast cancer treated with first-line taxane-trastuzumab-pertuzumab. Cancers. 2021;13:8. doi:10.3390/cancers13081964
   Web of Science ®Google Scholar
• Şahin AB, Cubukcu E, Ocak B, et al. Low pan-immune-inflammation-value predicts better chemotherapy response and survival in breast cancer patients treated with neoadjuvant chemotherapy. Sci Rep. 2021;11(1):14662. doi:10.1038/s41598-021-94184-7
   PubMed Web of Science ®Google Scholar
• Tsai CY, Hsieh SC, Liu CW, et al. Cross-talk among polymorphonuclear neutrophils, immune, and non-immune cells via released cytokines, granule proteins, microvesicles, and neutrophil extracellular trap formation: a novel concept of biology and pathobiology for neutrophils. Int J Mol Sci. 2021;22(6). doi:10.3390/ijms22063119
   Web of Science ®Google Scholar
• Denkert C, Loibl S, Noske A, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28(1):105–113. doi:10.1200/JCO.2009.23.7370
   PubMed Web of Science ®Google Scholar
• Yang L, Liu Q, Zhang X, et al. DNA of neutrophil extracellular traps promotes cancer metastasis via CCDC25. Nature. 2020;583(7814):133–138. doi:10.1038/s41586-020-2394-6
   PubMed Web of Science ®Google Scholar
• Olingy CE, Dinh HQ, Hedrick CC. Monocyte heterogeneity and functions in cancer. J Leukoc Biol. 2019;106(2):309–322. doi:10.1002/JLB.4RI0818-311R
   PubMed Web of Science ®Google Scholar
• Wang Y, Huang G, Li Z. Prognostic significance of inflammatory biomarkers in patients with breast cancer skeletal metastases. Cancer Manag Res. 2020;12:11463–11475. doi:10.2147/CMAR.S277291
   PubMed Web of Science ®Google Scholar
• Liu X, Meng QH, Ye Y, Hildebrandt MA, Gu J, Wu X. Prognostic significance of pretreatment serum levels of albumin, LDH and total bilirubin in patients with non-metastatic breast cancer. Carcinogenesis. 2015;36(2):243–248. doi:10.1093/carcin/bgu247
   PubMed Web of Science ®Google Scholar
• Hua X, Long ZQ, Huang X, et al. The Value of Prognostic Nutritional Index (PNI) in predicting survival and guiding radiotherapy of patients with T1-2N1 breast cancer. Front Oncol. 2019;9:1562. doi:10.3389/fonc.2019.01562
   PubMed Web of Science ®Google Scholar
• Tian G, Li G, Guan L, Yang Y, Li N. Pretreatment albumin-to-alkaline phosphatase ratio as a prognostic indicator in solid cancers: a meta-analysis with trial sequential analysis. Int J Surg. 2020;81:66–73. doi:10.1016/j.ijsu.2020.07.024
   PubMed Web of Science ®Google Scholar
• Zhou S, Wang H, Jiang W, Yu Q, Zeng A. Prognostic value of pretreatment albumin-to-alkaline phosphatase ratio in extensive-disease small-cell lung cancer: a retrospective cohort study. Cancer Manag Res. 2020;12:2015–2024. doi:10.2147/CMAR.S247967
   PubMed Web of Science ®Google Scholar
• Li S, Lu S, Liu X, Chen X. Association between the pretreatment albumin-to-alkaline phosphatase ratio and clinical outcomes in patients with bladder cancer treated with radical cystectomy: a retrospective cohort study. Front Oncol. 2021;11:664392. doi:10.3389/fonc.2021.664392
   PubMed Web of Science ®Google Scholar
• Poorvu PD, Gelber SI, Rosenberg SM, et al. Prognostic impact of the 21-gene recurrence score assay among young women with node-negative and node-positive ER-Positive/HER2-negative breast cancer. J Clin Oncol. 2020;38(7):725–733. doi:10.1200/JCO.19.01959
   PubMed Web of Science ®Google Scholar
• Ibraheem A, Olopade OI, Huo D. Propensity score analysis of the prognostic value of genomic assays for breast cancer in diverse populations using the National Cancer Data Base. Cancer. 2020;126(17):4013–4022. doi:10.1002/cncr.32956
   PubMed Web of Science ®Google Scholar
• Gnant M, Sestak I, Filipits M, et al. Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype. Ann Oncol. 2015;26(8):1685–1691. doi:10.1093/annonc/mdv215
   PubMed Web of Science ®Google Scholar
• Wallden B, Storhoff J, Nielsen T, et al. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. BMC Med Genomics. 2015;8:54. doi:10.1186/s12920-015-0129-6
   PubMed Web of Science ®Google Scholar
• Yuan J, Duan F, Zhai W, et al. An aging-related gene signature-based model for risk stratification and prognosis prediction in breast cancer. Int J Women’s Health. 2021;13:1053–1064. doi:10.2147/IJWH.S334756
   PubMed Web of Science ®Google Scholar
• Yersal O, Barutca S. Biological subtypes of breast cancer: prognostic and therapeutic implications. World J Clin Oncol. 2014;5(3):412–424. doi:10.5306/wjco.v5.i3.412
   PubMedGoogle Scholar